Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorpromazine + Temozolomide in Newly Diagnosed Glioblastoma Multiforme
NCT04224441Phase 2Unknown
- Start
- Dec 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Aminazin in glioblastoma multiforme (GBM). Primary endpoints: Evaluation of toxicity at 6 months and Progression-free survival at 6 months. Status: unknown.
02
Drugs
Aminazin
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04224441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224441.